Related Experiment Video
Updated: Sep 22, 2025

Implementation of Portable Emissions Measurement Systems PEMS for the Real-driving Emissions RDE Regulation in Europe
Published on: December 4, 2016
Getting better mileage with logically primed CARs.
Laurence C Chen1, Andrew J Hou1, Yvonne Y Chen2
1Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Chimeric antigen receptor (CAR)-T cell therapy shows promise for solid tumors by pairing synthetic Notch (synNotch) receptors with CARs. This engineering approach enhances T cell precision and potency against solid tumors.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Engineering
Background:
- Chimeric antigen receptor (CAR)-T cell therapy is highly effective against hematologic malignancies.
- Significant challenges remain in applying CAR-T cell therapy to solid tumors due to issues with specificity and efficacy.
- Current CAR-T cell limitations hinder their therapeutic potential in treating solid tumor cancers.
Purpose of the Study:
- To engineer T cells with improved specificity and potency for targeting solid tumors.
- To overcome the limitations of conventional CAR-T cell therapy in the context of solid tumors.
- To investigate the synergistic effects of combining synthetic Notch (synNotch) receptors with CARs for enhanced anti-tumor activity.
Main Methods:
- Development of novel T cells by integrating synthetic Notch (synNotch) receptors with chimeric antigen receptors (CARs).
- Utilizing genetic engineering techniques to co-express synNotch and CAR constructs in T cells.
- Pre-clinical evaluation of engineered T cell function against solid tumor models.
Main Results:
- Engineered T cells demonstrated enhanced specificity towards target antigens present on solid tumors.
- The combination of synNotch receptors and CARs resulted in improved T cell potency and effector function.
- Demonstrated a more precise and potent anti-tumor response compared to conventional CAR-T cells in solid tumor settings.
Conclusions:
- Pairing synNotch receptors with CARs represents a promising strategy to enhance T cell therapy for solid tumors.
- This engineered T cell approach offers a potential solution to improve efficacy and specificity in solid tumor treatment.
- Further research into synNotch-CAR T cells could lead to more effective cancer immunotherapies for solid malignancies.
Related Concept Videos
Turnover Number and Catalytic Efficiency
Chymotrypsin is a pancreatic enzyme that breaks down proteins during digestion....
Internal Combustion Engine
Otto and Diesel Cycle
Rolling Resistance: Problem Solving
Work Done in an Adiabatic Process
Mechanical Efficiency of Real Machines
However, in reality, no machine can be truly ideal, and all of them experience some...

